Cite
HARVARD Citation
Solomon, B. et al. (2023). Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet. 11 (4), pp. 354-366. [Online].